---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000971"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:47:28.741936+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LIXTE updates LB-100 clinical progress; two new trials started, $1.05M offering completed

## Summary
- First patient dosed in Phase 1b/2 trial combining LB-100 with GSK's dostarlimab for ovarian clear cell carcinoma.
- First patient dosed in colorectal trial at Netherlands Cancer Institute supported by Roche for MSI Low metastatic CRC.
- Received Notice of Allowance from USPTO for patent combining LB-100 with immunotherapies; also exclusive license agreement with NIH.
- Completed registered direct offering raising $1.05M for working capital and general corporate purposes.
- Two publications in Cancer Discovery and EMBO support LB-100's mechanism to force cancer cells to become vulnerable to immunotherapy.

## SEC filing metadata
- accession: 0001641172-25-000971
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000164117225000971/0001641172-25-000971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000164117225000971/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000971
- JSON: https://secwatch.observer/filing/0001641172-25-000971.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.